



GLYCOTOPE GROUP

Turning Glycomics into Health

Development and Production of Biopharmaceuticals

Glycotope is a global leader in optimizing the glycosylation of biopharmaceuticals.

With GlycoExpress™ the company offers one of the broadest platform technologies for the screening, development and production of glycosylated proteins. The clinical pipeline of currently 4 products of various types and targeting different indications underlines Glycotope's and its manufacturing arm Glycotope Biotechnology's competence to develop products that promise a significant improvement for healthcare. In parallel, Glycotope and Glycotope Biotechnology offer the entire range of contract R&D and manufacturing services from the gene down to the finished product.

After tremendous growth in the past years and now with more than 140 employees, Glycotope ranges among the largest Biotech companies in Germany.

Technology:

GlycoExpress™ is a unique and regulatory approved development and production technology based on a set of fully human cell-lines glycoengineered to deliver an improved glycosylation. Unmatched in its applicability, the system allows the improvement of activity, half-life time and immunogenicity for both antibodies and non-antibody proteins. Developed entirely by Glycotope and with superior production yields, the system permits an independent and cost effective development of improved biotherapeutics, coupled with a full patent protection.

Pipeline:

Glycotope currently investigates 4 products in clinical studies, both NBEs and improved follow-on biologics (BioBetter). The 3 anti-tumor antibodies and the protein-

Glycotope

Pipeline

Technologies

Contract Research

Glycotope Biotechnology

Analytical Services

Manufacturing Services

Immunodiagnostics



hormone FSH-GEX, all in phase I and progressing to phase II throughout 2012, have underlined Glyco-Express™ suitability to improve all classes of glycosylated proteins in multiple aspects. A further range of biopharmaceuticals is in various pre-clinical stages.

	PC	PI	P II	P III
PankoMab (NBE)				
CetuGEX (BioBetter Erbitux™)				
TrasGEX (Biobetter Herceptin™)				
FSH-GEX (Biobetter FSH)				
KaroMab (NBE)				

Manufacturing including Fill & Finish:

For many years Glycotope Biotechnology has been a competent and fully GMP-compliant manufacturing partner for the pharmaceutical industry and one of the first producers of recombinant proteins in Germany. 4 independent GMP-production suites allow fed-batch and perfusion fermentation of mammalian cell-lines. From USP & DSP, Cell-Banking, Analytics down to Fill & Finish, the company provides its customers with the complete range of contract manufacturing services necessary for a drug ready to be administered in clinical trials.

History

- 2011** TrasGEX™ and FSH-GEX™ start Phase I Expansion of DSP-capacities for production of up to 7 kg recombinant antibodies per year
- 2010** Glycotope's first BioBetter product CetuGEX™ starts clinical trials
Initial operation of 2 x 300 L perfusion reactors having a batch volume of up to 9,000 L each
Glycotope enrolls first patients in Phase I trial for its lead antibody PankoMab-GEXTM
- 2009** GlycoExpress receives regulatory approval
Glycotope Biotechnology approved for „Fill and Finish“ of clinical grade material
- 2008** Glycotope acquires manufacturing arm of Orpegen Pharma and forms Glycotope Biotechnology as GMP-Production unit of Glycotope. Orpegen Pharma was founded in 1982 in Heidelberg and among the first GMP-producers of recombinants in Germany (rhEPO in 1989, monoclonal antibodies in 1999)
- 2007** Glycotope wins Jossa Arznei GmbH as investor in one of the largest series A financing rounds in European Biotech history
- 2004** Orpegen inaugurates new multi-purpose biotechnology facility
- 2001** Foundation of Glycotope on the Biotech Campus in Berlin Buch

For more information please contact us

Glycotope GmbH | Robert-Roessle-Str. 10 | D-13125 Berlin | Germany | +49 (30) 9489 2600 | Fax: +49 (30) 9489 2609
www.glycotope.com | info@glycotope.com | Dr. Steffen Goletz, CEO, CSO & Founder | Dr. Franzpeter Bracht, CFO & CBO

Glycotope Biotechnology GmbH | Czernyring 22 | D-69115 Heidelberg, Germany | +49 (6221) 9105 0
Fax: +49 (6221) 9105 10 | www.glycotope-bt.com | info@glycotope-bt.com | Dr. Jens Pohl, COO